Injective
Why Injective is down 1.3% in the last hour
Analysis
Injective (INJ) slipped 1.3% over the past hour despite a generally positive headline, likely reflecting short-term profit-taking or muted immediate market impact. The Block reported that Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027, but the update appears to have been treated as longer-term optimism rather than a near-term catalyst for upside.
Contributing Factors (1)
Injective CEO Eric Chen expects US INJ ETFs to launch sooner than 2027
There are currently two ETF applications tied to INJ — the 21Shares Injective ETF and the Canary Staked INJ ETF.
Move Details
Explanation Confidence
High confidence in the explanation based on source reliability and timing.